Boehringer Ingelheim to sign cooperation with HISOAR in China
Within the the framework of this production alliance Boehringer Ingelheim complements its worldwide chemical production network with strong partners for the manufacturing of chemical intermediates for its active pharmaceutical ingredients (APIs).
Taizhou/China and Ingelheim/Germany, 28 August 2008 - Boehringer Ingelheim and Hisoar, a Chinese pharmaceutical production company based in Taizhou, today jointly announced a strategic production alliance in China. Within the the framework of this production alliance Boehringer Ingelheim complements its worldwide chemical production network with strong partners for the manufacturing of chemical intermediates for its active pharmaceutical ingredients (APIs). These chemicals will then be processed further in Boehringer Ingelheimâ€™s plants in Germany, Italy, Spain and the United States.
From September 2008 onwards, Boehringer Ingelheim will supply know-how as well as technical support for production to Hisoar. Hisoar in turn will invest into new specific production facilities for Boehringer Ingelheim at its new site in Chuannan. The production for Boehringer Ingelheim in Chuannan is planned to start in early 2009.
Mr. Bangpeng Luo, the Chairman of Hisoar commented: We are very pleased to have the opportunity to cooperate with Boehringer Ingelheim, a large multinational pharmaceutical company. This cooperation, both from the technical and the management level, will raise Hisoarâ€™s market positioning and standing and it will create an unusual benefit for Hisoar to enter the international levelof raw material suppliers, and indicates that Hisoar has come a big step forward towards internationalization.â€ť
Dr Hans-JĂĽrgen Leuchs, Member of the Board of Managing Directors and responsible for the Corporate Board Division Operations of Boehringer Ingelheim added, â€śBoehringer Ingelheim is looking forward to a fruitful cooperation with our Chinese partner to have in future more flexibility, short production timelines and an appropriate capacity for the continuously growing demand for Boehringer Ingelheimâ€™s medications across the globe.â€ť... more